Abstract
e15580 Background: A phase II trial of combination paclitaxel and carboplatin (PC) was performed in patients with advanced or recurrent endometrial cancer in Fudan University Shanghai Cancer Center to estimate the efficacy and toxicity. Methods: Eligible patients with measurable disease were enrolled between July 2007 and September 2010. Six courses of paclitaxel (135 mg/m2) and carboplatinum (AUC 5) on day 1 every 3 weeks were administered in outpatients. Response rates were evaluated according to the response evaluation criteria in solid tumors. Results: Forty patients with assessable disease enrolled, 16 with residual disease after primary or second cyto-reductive surgery (group A), 24 with unresectable recurrent or metastatic disease (group B). In the complete series, 12 CR (30%) and 16 (40%) PR were recorded, with an ORR (overall response rate) of 70% (95% CI 53%~83%). Significantly more patients in group A experienced CR than group B (56.2% VS 16.67%, P=0.009), but the difference of ORR was not stat...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
